Illumina just released its Q3 2026 report and the market reacted sharply. The stock fell 18.6% today to about US$236, even though the company posted Basic EPS of US$1.46 and net income from continuing operations of US$220 million for the quarter. Traders focused on the valuation concern following a rich 39.9x trailing P/E. The fundamentals presented a more measured picture. Margins stayed healthy, guidance for full year revenue and earnings moved higher, and free cash flow remained solid. The key question now is whether this selloff reflects fear or an overreaction to a crowded trade.
Love Illumina's solid margins and free cash flow but worried about paying up for a 39.9x trailing P/E in a crowded trade? You may want to explore our 33 high quality undervalued stocks for ideas that pair comparatively lower valuations with fundamental strength.
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$1,129 million vs. US$1,084 million (up 4.2%)
-
Net Income from Continuing Operations (Q3 2026 vs. Q3 2025):US$220 million vs. US$150 million (up 46.7%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$1.46 vs. US$0.98 (up 48.6%)
-
Net Profit Margin (Trailing 12 Months vs. Prior Year):19.7% vs. 16.5% (improved by 3.2 percentage points)
Tired of scrolling through dense earnings releases and raw figures to piece together Illumina's story? Get a clean visual snapshot of Illumina's valuation and how the market is pricing its latest results in the interactive company report for Illumina.
Evaluating Illumina's Bull Case On Clinical And Data Mix
The bullish story hangs on Illumina turning clinical and data heavy offerings into a richer earnings engine over time.
"The main factor that would need to go right is that Illumina continues to convert clinical demand, multiomics products and BioInsight into higher margin consumables and data revenue while managing research softness, China constraints and legal or competitive pressures."
Q3 shows real traction on that goal. Clinical consumables grew in the mid teens in Rest of World, while research and applied consumables declined mid to high single digits. Sequencing services and other, where Billion Cell Atlas and BioInsight sit, rose faster than the group and helped Illumina lift operating margin to 25%, ahead of prior guidance.
One Narrative disagrees with today's price. → See where this Narrative says Illumina should trade .
Illumina Bear Case: Margin Fears Versus Mixed Signals
Bears argue Illumina's clinical push comes with legal headaches and higher input costs that could eat into profitability and blunt the NovaSeq X payoff.
"Although Illumina has expanded non GAAP operating margin and reaffirmed its margin outlook, the need to secure additional memory inventory ahead of rising prices and absorb higher freight expenses indicates that elevated component and logistics costs could persist and limit further gross margin improvement and future net margin expansion."
Q3 non GAAP operating margin reached 25%, 100 bps above guidance, and full year margin expectations moved higher. That directly contradicts the idea of near term margin compression. The miss is that management still flags research and applied consumables declines and China restrictions, so the durability of this margin level remains unproven.
Hunt For Mispriced Earnings Power
Illumina shows how a margin narrative can still coincide with a sharp valuation reset. The real opportunity is in stocks that may be misaligned with fundamentals before sentiment adjusts.
-
Company 1 - 21% below our estimate - leans into AI driven data center optics as new capacity shifts toward photonics and advanced packaging programs.
-
Company 2 - 29% below our estimate - uses AI centric networking hardware and cloud services to move contracts toward recurring, higher margin consumption models.
-
Company 3 - 38% below our estimate - expands high horsepower engine capacity as data center power agreements reshape where new capital and HELM engines are deployed.
Three companies from the same screener. Open the full list of 33 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ILMN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
